je.st
news
Why Gilead Is Still A Growth Stock - Focus On HIV And China, With Projections For 2016
2015-12-08 14:07:47| Biotech - Topix.net
Yet it continues to demonstrate growing earnings power from medical trends in HIV, new products in HIV and HCV, and geographic expansion. At its current valuation, I believe that Gilead Sciences is reasonably valued even if its non-HCV, non-HIV pipeline flops.
Tags: for
with
china
stock
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||